% | $
Quotes you view appear here for quick access.

Genta Incorporated Message Board

  • acricketeer acricketeer Apr 2, 2004 8:27 AM Flag

    Most Biotechs Are Raising Money Now

    There's a limited window of opportunity and one can go down the list and see the number of shelfs, including debt financings and secondaries in the sector.
    A shelf offering, once cleared through the SEC, gives the Company the right, but not the obligation to issue a range of securities. They're getting the filing out of the way. However, it doesn't mean they'll do it at dilutive valuations.
    Most importantly, their ability to raise money will be a key factor in the success of their stock. If Genasense were thought to be dead in the water, then no institution in their right mind would buy stock ahead of ODAC. However, if they are confident (through winks and nods in Rockville) that Genasense will be approved, they may be able to pre-sell the deal. A shelf is far more favorable to shareholders than a PIPE (which is done at a big discount to market price). I seriously doubt that the offering will be done before ODAC. This will also dilute AVE's stake, unless they choose to participate, as well.

    SortNewest  |  Oldest  |  Most Replied Expand all replies